Currently, treatment of hereditary angioedema with recombinant SERPING1 (Ruconest, Salix Pharmaceuticals) is approved in some jurisdictions73, and it could be interesting to investigate it for efficacy in SARS-CoV-2 cases, although it is important to be mindful of how angioedema pathophysiology is different from that of COVID-19. The gene discussed is SERPING1; the disease is hereditary angioedema.